Holen Sie sich die Stockscreener-App
19.76
0.41%
0.08
Handel nachbörslich:
19.74
-0.02
-0.10%
Schlusskurs vom Vortag:
$19.68
Offen:
$19.68
24-Stunden-Volumen:
650.14K
Relative Volume:
1.04
Marktkapitalisierung:
$6.96B
Einnahmen:
$4.68B
Nettoeinkommen (Verlust:
$-368.00M
KGV:
-33.33
EPS:
-0.5929
Netto-Cashflow:
$-58.00M
1W Leistung:
-3.37%
1M Leistung:
-4.22%
6M Leistung:
+34.88%
1J Leistung:
+26.34%
1-Tages-Spanne:
$19.52
$20.23
1-Wochen-Bereich:
$19.44
$20.33
52-Wochen-Spanne:
$13.16
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BLCO | 19.76 | 6.96B | 4.68B | -368.00M | -58.00M | -0.5929 |
| ISRG | 531.64 | 190.09B | 7.87B | 2.24B | 586.00M | 4.25 |
| BDX | 224.10 | 65.14B | 20.18B | 1.73B | 3.07B | 5.51 |
| ALC | 85.81 | 42.44B | 9.76B | 1.16B | 665.00M | 0.72 |
| RMD | 239.42 | 34.99B | 4.81B | 1.11B | 1.35B | 6.16 |
| WST | 307.21 | 22.29B | 2.88B | 499.60M | 321.60M | 7.41 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs - Business Wire
Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale - Nasdaq
Bausch & Lomb Secures $400 Million in New Term Loans - Investing.com India
Bausch & Lomb Secures $400 Million in New Term Loans By Investing.com - Investing.com South Africa
Bausch + Lomb Corporation (NYSE:BLCO) Q3 2024 Earnings Call Transcript - Insider Monkey
Bausch & Lomb stock target lifted, keeps buy on strong Q3 results - Investing.com
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Orthokeratology Lens Market is expected to Double Its Size - openPR
Bausch + Lomb posts top-line beat, raises full-year outlook - Investing.com
Bausch + Lomb: Q3 Earnings Snapshot - Marketscreener.com
Bausch + Lomb Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bausch + Lomb Announces Third-Quarter 2024 Results - Business Wire
Bausch & Lomb Corp (TSX:BLCO) Q3 2024 Earnings Report Preview: W - GuruFocus.com
BAUSCH & LOMB CORP (BLCO)Sunday, Jul 28, 2024 - Smartkarma
Dry Eye Treatment Market to Hit $9.3 Billion: Bausch + Lomb Acquires XIIDRA, New FDA Approvals Boost Options - openPR
Bausch + Lomb price target raised to $23 from $20 at RBC Capital - Yahoo Finance
Bausch + Lomb (BLCO) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
RBC raises Bausch & Lomb stock price target ahead of Q3 results - Investing.com Canada
Bausch + Lomb (NYSE:BLCO) PT Raised to $23.00 - MarketBeat
Banks, Private Credit Vie for $5 Billion Bausch + Lomb Debt - Bloomberg
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags - Benzinga
Bausch & Lomb gains amid report TPG, Blackstone working on joint bid - MSN
Banks, Private Credit Vie for $5 Billion Bausch Lomb Financing | Today News - Mint
Exclusive | Bausch Health Rejects Bondholders’ Debt Proposals, Explores Sale of Vision Care UnitWSJ - The Wall Street Journal
Bausch & Lomb shares upgraded, price target raised By Investing.com - Investing.com UK
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday - MSN
Bausch + Lomb Corp [BLCO] Investment Guide: What You Need to Know - Knox Daily
Why Bausch + Lomb Stock Soared by Over 7% on Monday - Yahoo Finance
TPG and Blackstone team up to bid for eyecare group Bausch + Lomb - Financial Times
Anthony Wallace of Bausch + Lomb talks about enVista Envy FDA approval - Ophthalmology Times
Bausch + Lomb wins FDA nod for enVista Envy range of intraocular lenses - Medical Device Network
Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid - Yahoo Finance
Bausch + Lomb (NYSE:BLCO) Sets New 1-Year HighHere's What Happened - MarketBeat
Bausch + Lomb stock hits 52-week high at $21.19 amid robust growth - Investing.com UK
S&P 500 Futures Rise in Premarket Trading; Bausch + Lomb, MicroStrategy Lead - Barron's
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens - Business Wire
Bausch Lomb Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Bausch + Lomb Corp (BLCO) - SETE News
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 - Business Wire
Marshall Wace LLP Takes $1.91 Million Position in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch + Lomb eyes new ecommerce opportunity - Digital Commerce 360
Bausch + Lomb price target raised to $19 from $17 at Evercore ISI - Yahoo Finance
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States - Business Wire
Clearline Capital LP Acquires 411,404 Shares of Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Wall Street SWOT: Bausch + Lomb stock rides wave of eye health innovation - Investing.com
Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Epinephrine Autoinjectors Industry Research Business Report 2024 Featuring ALK-Abello, Bausch + Lomb, Emerade, Teva Pharmaceutical - Yahoo Finance
Bausch Health: A Buyout Bid Could Be The Ticket To Unlock Value - Barchart
Gabelli Funds LLC Purchases 78,000 Shares of Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.70%
3.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):